Evogene

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene’s main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

everads therapy ltd

Everads Therapy is an early-stage life sciences company developing the next generation of retinal treatment delivery technologies. With the goal of overcoming significant challenges in current treatment methodologies for retinal and macular diseases, Everads' delivery system offers the promise of improving the efficacy and safety of existing and potential drug therapies. Established in 2017, Everads Therapy operates within the RAD Biomed incubator in Tel Aviv, Israel. Its underlying technologies have been licensed from the Sheba Medical Center at Tel Hashomer.

Identifai Genetics

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

Karius

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

Nkarta, Inc.

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.